Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00035022 | Study of Intravenous BCX-1777 in Relapsed or Refractory Aggressive T-Cell Leukemias or Lymphomas | PHASE1 | COMPLETED | 71 | — | — | Aug 1, 2001 | Mar 1, 2004 | Jan 13, 2006 | 1 | United States |
| Name | Type | Description |
|---|---|---|
| BCX-1777 | DRUG | - |
Inclusion Criteria: * Previously treated, relapsed or refractory aggressive T-cell malignancies (leukemias and lymphomas) histologically proven with measurable disease. * Capable of only limited self-care, confined to bed or chair more than 50% of waking hours. * All ages are eligible. Pediatric pa...